Trial Profile
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Encequidar+paclitaxel (Primary)
- Indications Haemangiosarcoma; Skin cancer
- Focus Therapeutic Use
- Sponsors Athenex
- 18 May 2023 Status changed from active, no longer recruiting to completed.
- 31 Jan 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.
- 31 Jan 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.